NASDAQ:LUCD Lucid Diagnostics (LUCD) Stock Price, News & Analysis $1.26 +0.06 (+5.00%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.25 -0.01 (-0.40%) As of 08/29/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lucid Diagnostics Stock (NASDAQ:LUCD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lucid Diagnostics alerts:Sign Up Key Stats Today's Range$1.21▼$1.3150-Day Range$0.98▼$1.2652-Week Range$0.73▼$1.80Volume1.12 million shsAverage Volume746,561 shsMarket Capitalization$136.68 millionP/E RatioN/ADividend YieldN/APrice Target$3.55Consensus RatingBuy Company Overview Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc. Read More Lucid Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreLUCD MarketRank™: Lucid Diagnostics scored higher than 56% of companies evaluated by MarketBeat, and ranked 469th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingLucid Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLucid Diagnostics has only been the subject of 2 research reports in the past 90 days.Read more about Lucid Diagnostics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lucid Diagnostics are expected to grow in the coming year, from ($0.84) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lucid Diagnostics is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lucid Diagnostics is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Lucid Diagnostics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.09% of the float of Lucid Diagnostics has been sold short.Short Interest Ratio / Days to CoverLucid Diagnostics has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Lucid Diagnostics has recently increased by 10.23%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLucid Diagnostics does not currently pay a dividend.Dividend GrowthLucid Diagnostics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.09% of the float of Lucid Diagnostics has been sold short.Short Interest Ratio / Days to CoverLucid Diagnostics has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Lucid Diagnostics has recently increased by 10.23%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News Sentiment0.82 News SentimentLucid Diagnostics has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.05 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Lucid Diagnostics this week, compared to 2 articles on an average week.Search Interest4 people have searched for LUCD on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added Lucid Diagnostics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Lucid Diagnostics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $102,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 6.80% of the stock of Lucid Diagnostics is held by insiders.Percentage Held by Institutions74.01% of the stock of Lucid Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lucid Diagnostics' insider trading history. Receive LUCD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lucid Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LUCD Stock News HeadlinesInsider Buying: Lucid Diagnostics (NASDAQ:LUCD) Director Acquires 100,000 Shares of StockAugust 23, 2025 | insidertrades.comCanaccord Genuity Remains a Buy on Lucid Diagnostics (LUCD)August 29 at 5:32 PM | theglobeandmail.comA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.August 30 at 2:00 AM | Investors Alley (Ad)Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025August 27 at 8:00 AM | prnewswire.comPAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging TechnologyAugust 26, 2025 | prnewswire.comLucid Diagnostics (LUCD) Gets a Buy from BTIGAugust 22, 2025 | theglobeandmail.comLucid Diagnostics reports Q2 non-GAAP EPS (10c), consensus (10c)August 15, 2025 | msn.comPAVmed Provides Business Update and Reports Second Quarter 2025 Financial ResultsAugust 14, 2025 | prnewswire.comSee More Headlines LUCD Stock Analysis - Frequently Asked Questions How have LUCD shares performed this year? Lucid Diagnostics' stock was trading at $0.8187 at the beginning of the year. Since then, LUCD shares have increased by 53.9% and is now trading at $1.26. How were Lucid Diagnostics' earnings last quarter? Lucid Diagnostics Inc. (NASDAQ:LUCD) released its earnings results on Tuesday, March, 26th. The company reported ($0.26) earnings per share (EPS) for the quarter. The company had revenue of $1.04 million for the quarter. Read the conference call transcript. When did Lucid Diagnostics IPO? Lucid Diagnostics (LUCD) raised $75 million in an initial public offering (IPO) on Thursday, October 14th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Who are Lucid Diagnostics' major shareholders? Top institutional investors of Lucid Diagnostics include Geode Capital Management LLC (1.46%), New York State Common Retirement Fund (0.08%), Parallel Advisors LLC (0.04%) and MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. (0.03%). Insiders that own company stock include Dennis Matheis and Stanley Lapidus. View institutional ownership trends. How do I buy shares of Lucid Diagnostics? Shares of LUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lucid Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lucid Diagnostics investors own include Meta Platforms (META), NVIDIA (NVDA), Taiwan Semiconductor Manufacturing (TSM), Advanced Micro Devices (AMD), Netflix (NFLX), Clean Energy Fuels (CLNE) and Baidu (BIDU). Company Calendar Last Earnings3/26/2024Today8/30/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:LUCD CIK1799011 Webwww.luciddx.com Phone212-949-4319FaxN/AEmployees70Year FoundedN/APrice Target and Rating Average Price Target for Lucid Diagnostics$3.55 High Price Target$7.75 Low Price Target$2.00 Potential Upside/Downside+181.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.53 million Net Margins-1,476.35% Pretax Margin-1,267.41% Return on EquityN/A Return on Assets-120.43% Debt Debt-to-Equity RatioN/A Current Ratio1.15 Quick Ratio1.13 Sales & Book Value Annual Sales$4.36 million Price / Sales31.35 Cash FlowN/A Price / Cash FlowN/A Book Value($0.43) per share Price / Book-2.93Miscellaneous Outstanding Shares108,477,000Free Float101,101,000Market Cap$136.68 million OptionableNo Data Beta1.21 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:LUCD) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lucid Diagnostics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lucid Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.